AEZS Company Profile and Key Details
Aeterna Zentaris Inc.
AEZS Stock Price Chart
Stock Price Today
Aeterna Zentaris Inc. (AEZS) stock surged +2.14%, trading at $5.72 on NASDAQ, up from the previous close of $5.60. The stock opened at $5.51, fluctuating between $5.48 and $5.93 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Company Information
| Employees | 12 |
| Beta | 2.26 |
| Sales or Revenue | $4.58M |
| 5Y Sales Change% | -0.977% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Aeterna Zentaris Inc. (NASDAQ: AEZS) stock price is $5.72 in the last trading session. During the trading session, AEZS stock reached the peak price of $5.93 while $5.48 was the lowest point it dropped to. The percentage change in AEZS stock occurred in the recent session was 2.14% while the dollar amount for the price change in AEZS stock was $0.12.
The NASDAQ listed AEZS is part of Biotechnology industry that operates in the broader Healthcare sector. Aeterna Zentaris Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Giuliano La Fratta
Senior Vice President of Fin. & Chief Financial Officer
Ms. Amélie Métivier
Assistant Sec.
Dr. Klaus Paulini Ph.D.
Pres, Chief Executive Officer & Executive Director
Dr. Nicola Ammer M.D.
Chief Medical Officer & Senior Vice President of Clinical Devel.
Dr. Matthias Gerlach
Senior Vice President Manufacturing & Supply Chain
Dr. Eckhard G. Guenther Ph.D.
Senior Vice President of Bus. Devel. & Alliance Management and MD of AEZS Germany
Dr. Michael Teifel
Senior Vice President of Non-Clinical Devel. & Chief Scientific Officer
Dr. Michael Teifel Ph.D.
Senior Vice President of Non-Clinical Devel. & Chief Scientific Officer
AEZS's closing price is 3,713.33% higher than its 52-week low of $0.15 where as its distance from 52-week high of $9.32 is -38.64%.
Number of AEZS employees currently stands at 12.
Official Website of AEZS is: https://www.zentaris.com
AEZS could be contacted at phone 843 900 3223 and can also be accessed through its website. AEZS operates from 315 Sigma Drive, Summerville, SC 29486, United States.
AEZS stock volume for the day was 7.51K shares. The average number of AEZS shares traded daily for last 3 months was 6.04K.
The market value of AEZS currently stands at $17.51M with its latest stock price at $5.72 and 3.06M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com